Summary
Synopsis: Since previously reviewed in the Journal (Vol. 12, No. 2), metoclopramide has been confirmed as an effective drug in treating and preventing various types of vomiting and as a useful agent in oesophageal reflux disease, gastroparesis, dyspepsia, and in a variety of functional gastrointestinal disorders. Of considerable importance is the recent evidence of its efficacy when administered intravenously in high dosages in preventing severe vomiting associated with cisplatin. Good results have been achieved in patients not previously treated with cisplatin, but further studies are needed to determine its level of efficacy in patients who have experienced severe vomiting during earlier courses of cytotoxic therapy. Side effects consisting of mild sedation, diarrhoea and reversible extrapyramidal reactions have occurred, but are tolerated by many patients.
Pharmacodynamic Studies: Pharmacodynamic studies in man have shown that oral and intravenous metoclopramide rapidly influences gastrointestinal tract motility. The effect of the drug in increasing lower oesophageal sphincter pressure is more marked in volunteers than patients with reflux oesophagitis or pregnant patients, and appears to be directly related to basal pressure, dose and route of administration. Gastric emptying studies employing radioisotope-labelled liquid and solid meals have demonstrated increased emptying in patients with delayed gastric emptying associated with diabetes, vagotomy and other gastric surgery. The effect of metoclopramide on gastric contractions is most pronounced in the antrum. Metoclopramide stimulates contraction of intestinal smooth muscle, resulting in a decreased transit time through the small intestine, but any effect on colonic activity remains to be clarified. Metoclopramide is effective in preventing apomorphine-induced vomiting in man, and in animals prevents vomiting induced by apomorphine, hydergine, reserpine, tetrodotoxin and copper sulphate, by raising the threshold for vomiting at the chemoreceptor trigger zone as well as by peripheral mechanisms. Other effects on the gastrointestinal tract are thought to result from inhibition of dopaminergic receptors, potentiation of cholinergic effects and/or a direct action on smooth muscle.
The neuroleptic-like central nervous system effects of metoclopramide probably result from blockade of cerebral dopamine receptors by the parent drug rather than by a metabolite.
Oral or intravenous metoclopramide stimulates prolactin release in all recipients.
Pharmacokinetics: Peak plasma metoclopramide concentrations occur within 1 hour of oral administration. On average, concentrations 1 hour after 20 and 40mg doses are about 40 and 80 ng/ml, respectively, but may show interindividual variation because of ‘first-pass’ hepatic metabolism. In crossover studies, relative bioavailability was lower after rectal administration of 40mg than after an oral dose of 26.7mg. The mean volume of distribution is about 2 to 3 L/kg. Metoclopramide readily enters breast milk where drug concentrations exceed those in plasma 2 hours after oral administration. 80% of an oral dose is excreted in the urine within 24 hours, either as unchanged drug (20%) or sulphate and glucuronide conjugates of metoclopramide. Elimination half-life has been reported as 2.6 to 5 hours in healthy subjects and around 14 hours in patients with moderate to severe renal impairment.
Therapeutic Trials: Controlled trials have shown oral metoclopramide 30 to 40mg daily to alleviate the symptoms of gastro-oesophageal reflux relative to placebo and in some studies to also increase lower oesophageal sphincter pressure. However, as with many other drugs used in oesophageal reflux disease, endoscopic healing of oesophagitis has still to be adequately demonstrated with metoclopramide.
Some patients with gastroparesis associated with diabetes mellitus or vagotomy have benefited from treatment with metoclopramide 40mg daily. However, there are no established criteria to predict which patients may benefit most and gastric emptying rates are not a reliable indication of response.
Metoclopramide has been successfully used to treat dyspepsia, being more effective than placebo, the anticholinergic drug pipenzolate and the antiemetic agent prochlorperazine. Similarly, metoclopramide appears to be useful in a variety of functional gastrointestinal disorders including irritable bowel syndrome, spastic constipation, and functional diarrhoea but studies in these conditions and in dyspepsia have generally been poorly designed. There is no firm evidence that the drug promotes the healing of peptic ulcer.
Results of studies in the prevention of postoperative vomiting have been variable, with metoclopramide proving effective and comparable with the peripheral dopamine antagonist domperidone when administered intravenously immediately prior to general anaesthesia. As with other drugs used in prevention of postoperative vomiting, response to metoclopramide has been influenced by the interval between administration and induction of anaesthesia, the anaesthetic drugs, postoperative use of narcotic analgesics and variation in surgical procedures.
Recent well conducted studies have shown high dose intravenous metoclopramide (1 to 2 mg/kg for 5 or 6 doses) to be effective in preventing the severe vomiting caused by cisplatin therapy (50 to 120 mg/m2). Best results to date have been achieved in patients not previously exposed to antineoplastic drugs, and in patients previously treated with cisplatin whose initial vomiting had been well controlled. In patients receiving cisplatin for the first time, high dose metoclopramide was superior to placebo, intramuscular prochlorperazine and oral tetrahydrocannabinol.
Metoclopramide has been used to control vomiting associated with narcotic analgesics, radiation therapy, pregnancy, gastroenteritis, gastric carcinoma, hepatic and biliary disorders, chronic renal failure, cardiac disease and alcoholism. The delayed absorption caused by poor gastric emptying associated with migraine attacks appears to be corrected by metoclopramide, resulting in earlier attainment of therapeutic plasma concentrations of concomitantly administered analgesics, but this has yet to be confirmed in appropriately designed controlled trials.
The drug has been widely used as an adjunct in radiological examination of the small bowel to facilitate the passage of barium, and is useful in facilitating intubation and in speeding the passage of biopsy capsules across the pylorus.
Side Effects: At usual therapeutic doses metoclopramide is well tolerated. Side effects are generally mild and transient and seldom necessitate withdrawal of the drug. They consist principally of drowsiness, restlessness, bowel disturbances, dizziness and faintness after oral or parenteral administration. At usual doses, extrapyramidal effects are infrequent in adults, but occur more often at the higher dosages used to prevent vomiting caused by antineoplastic drugs and in patients with renal failure. These reactions respond to reduction of dose, withdrawal of the drug, or treatment with intramuscular benztropine, diphenhy-dramine or diazepam. A dose-related increase in drowsiness is evident with high intravenous doses used to treat cisplatin-induced vomiting. Further experience is needed to determine the incidence of side effects with high and intermediate doses of intravenous metoclopramide, particularly in children and young adults.
Dosage: The usual oral intramuscular or intravenous dose in adults is 10mg 3 or 4 times daily before meals or before symptoms are likely to occur. Children under 14 years should receive 0.1 mg/kg per dose, the total daily dose not to exceed 0.5 mg/kg/day.
For diagnostic purposes, the adult dose is 20mg orally 20 minutes before examination or 10 to 20mg parenterally 5 minutes before examination.
For the prevention of cisplatin-induced vomiting in adults, metoclopramide should be iluted in 50ml of an intravenous solution and infused over a period of at least 15 minutes. At present it is recommended that administration should begin 30 minutes before cisplatin and be repeated 2-hourly for 2 doses and 3-hourly for 3 doses. The initial doses should be 2 mg/kg, and if vomiting is controlled, subsequent doses may be decreased to 1 mg/g. However, the optimum dosage recommendations, particularly in children and young adults, remain to be established.
This is a preview of subscription content, access via your institution.
References
Agabiti-Rosei, E.; Alicandri, C.L. and Corea, L.: Hypertensive crisis in patients with phaeochromocytoma given metoclopramide. Lancet 1: 600 (1977).
Albibi, R. and McCallum, R.W.: Metoclopramide: Pharmacology and clinical application. Annals of Internal Medicine 98: 86–95 (1983).
Andersen, O.P.; Hansen, P. and Madsen, H.: Hyperprolactinemic amenorrhea induced by metoclopramide (Primperan). Acta Obstetricia et Gynaecologica Scandinavica 60: 341–342 (1981).
Aono, T.; Shioji, T.; Kinugasa, T.; Onishi, T. and Kurachi, K.: Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. Journal of Clinical Endocrinology and Metabolism 47(3): 675–680 (1978).
Arndt, K.A. and Jick, H.: Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. Journal of the American Medical Association 235: 918–923 (1976).
Arnold, C.J.; Ribiero, V. and Bulkin, W.: Metoclopramide (MCP) vs prochlorperazine (PCP) in the prevention of vomiting from diamminedichloroplatinum (DDP). American Academy of Cancer Research. Proceedings of American Society of Clinical Oncology 21: 344 (1980).
Arvanitakis, C; Gonzalez, G. and Rhodes, J.B.: The role of metoclopramide in peroral jejunal biopsy. A controlled randomized trial. Digestive Diseases 21: 880–884 (1976).
Awerbuch, M.S.; Milazzo, S.C.; Reiner, R.G. and Alp, M.H.: Metoclopramide. Management of gastrointestinal intolerance in rheumatoid arthritis patients. Medical Journal of Australia 1 (9); 478–479 (1981).
Banke, L.: Research on the action of metoclopramide in the gastro-intestinal tract. In Modern Gastroenterology (Proceedings of VIII International Congress on Gastroenterology, Prague, July 1968), pp 571–572 (Schattauer, Stuttgart 1969).
Bateman, D.N. and Davies, D.S.: Pharmacokinetics of metoclopramide. Lancet 1: 166 (1979).
Bateman, D.N. and Gokal, R.: Metoclopramide in renal failure. Lancet 1: 982 (1980).
Bateman, D.N.; Kahn, G; Legg, N.J. and Reid, J.L.: Metoclopramide in Parkinson’s disease. Clinical Pharmacology and Therapeutics 24: 459–464 (1978a).
Bateman, D.N.; Kahn, G; Mashiter, K. and Davies, D.S.: Phar-macokinetic and concentration effect studies with intravenous metoclopramide. British Journal of Clinical Pharmacology 4: 640P (1978b).
Bateman, D.N.; Dutta, D.K.; McClelland, H.A. and Rawlins, M.D.: Metoclopramide and haloperidol in tardive dyskinesia. British Journal of Psychiatry 135: 505–508 (1979a).
Bateman, D.N.; Kahn, C. and Davies, D.S.: Concentration effect studies with oral metoclopramide. British Journal of Clinical Pharmacology 8: 179–182 (1979b).
Bateman, D.N.; Kahn, C. and Davies, D.S.: The pharmacokinetics of metoclopramide in man with observations in the dog. British Journal of Clinical Pharmacology 9: 371–377 (1980).
Bateman, D.N.; Gokal, R.; Dodd, T.R.P. and Blain, P.G.: The pharmacokinetics of single doses of metoclopramide in renal failure. Europ. J. Clin. Pharmacol. 19: 437–441 (1981).
Bateman, D.N.; Craft, A.W.; Nicholson, E. and Pearson, A.D.J.: Dystonic reactions and the pharmacokinetics of metoclopramide in children. British Journal of Clinical Pharmacology (In press, 1983).
Battle, W.M.; Alavi, A.; Braunstein, S. and Snape, W.J. Jr: Effect of metoclopramide on gastroparesis in diabetes mellitus. Clinical Research 27(3): 577A (1979).
Battle, W.M.; Snape, W.J.; Alavi, A.; Cohen, S. and Braunstein, S.: Colonic dysfunction in diabetes mellitus. Gastroenterology 79: 1217–1221 (1980).
Battle, W.M.; Snape, W.J.; Wright, S.; Sullivan, M.A.; Cohen, S.; Meyers, A. and Tuthill, R.: Abnormal colonie motility in progressive systemic sclerosis. Annals of Internal Medicine 94: 749–752 (1981).
Baumann, H.W.; McCallum, R.W. and Sturdevant, R.A.L.: Metoclopramide: A possible antagonist of dopamine in the esophagus of man. Gastroenterology 70(5): 862 (1976).
Baumann, H.W.; Sturdevant, R.A.L. and McCallum, R.W.: L-Dopa inhibits metoclopramide stimulation of the lower esophageal sphincter in man. American Journal of Digestive Diseases 24: (4): 289–295 (1979).
Behar, J.: Reflux esophagitis. Pathogenesis, diagnosis and management. Archives of Internal Medicine 136: 560–566 (1976).
Behar, J. and Biancani, P.: Effect of oral metoclopramide on gastroesophageal reflux in the post-cibal state. Gastroenterology 70(3): 331–335 (1976).
Behar, J. and Ramsby, G.: Gastric emptying and antral motility in reflux esophagitis. Effect of oral metoclopramide. Gastroenterology 74(2): 253–256 (1978).
Behar, J.; Deren, J.; Falchuk, K.; Hersh, T.; Ippolitti, A.; McCallum, R.; Olsen, H.; Rakatansky, H.; Rhodes, J. and Salen, G.: A multi-center placebo-controlled clinical trial of reglan tablets in diabetic gastroparesis. A.H. Robins Co. Research Report 81-0132.
Berkowitz, D.M. and McCallum, R.W.: Interaction of levodopa and metoclopramide on gastric emptying. Clinical Pharmacology and Therapeutics 27(3): 414–420 (1980).
Berkowitz, D.M.; Metzger, W.H. and Sturdevant, R.A.L.: Oral metoclopramide in diabetic gastroparesis and in chronic gastric retention after gastric surgery. Gastroenterology 70(5): 863 (1976).
Bernheim, J.L.; Shapira, J.; Arber, I. and Shapiro, M.S.: The effect of TRH and metoclopramide on human subjects. Clinical Research 27: 248A (1979).
Basser, G.M.; Delitala, G.; Grossman, A.; Stubbs, W.A. and Yeo, T.: Chlorpromazine, haloperidol, metoclopramide and dom-peridone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. British Journal of Pharmacology 71: 569–573 (1980).
Birtley, R.D.N. and Baines, M.W.: The effects of metoclopramide on some isolated intestinal preparations. Postgraduate Medical Journal 49 (Suppl. 4): 13 (1973).
Block, W.; Pingoud, A.; Khan, M. and Kjellerup, P.: The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. Arzneimittel-Forschung 31(6): 1041–1045 (1981).
Borenstein, P. and Bles, G.: Effets cliniques et électro-encéphalographiques du metoclopramide en psychiatrie. Thérapie 20: 975 (1965).
Brady, P.G. and Richardson, R.: Gastric bezoar formation secondary to gastroparesis diabeticorum. Archives of Internal Medicine 137(12): 1729 (1977).
Brandes, J.M.; Itskovitz, J.; Fisher, M.; Shen-Orr, Z. and Barzilai, D.: The acute effect of metoclopramide on plasma prolactin during pregnancy. Acta Obstetrica et Gynaecologica Scandi-navica 60: 243–245 (1981).
Braverman, D. and Bogoch, A.: Metoclopramide for gastroparesis diabeticorum. Diabetes Care 1(6): 356–359 (1978).
Bremner, CG. and Bremner, C.H.: Augmentation of lower oesophageal sphincter tone with metoclopramide (Maxolon) in normals and in patients with sphincter incompetence. South African Journal of Surgery 10: 211 (1972).
Bright-Asare, P. and El-Bassoussi, M.: Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroe-sophageal reflux. Journal of Clinical Gastroenterology 2: 149–156 (1980).
Brock-Utne, J.G.; Rubin, R.; Downing, J.W.; Dimopoulos, G.E.; Moshal, M.G. and Naicker, M.: The administration of metoclopramide with atropine. A drug interaction effect on the gastro-oesophageal sphincter in man. Anaesthesia 31: 11 Soil 90 (1976).
Brock-Utne, J.G.; Dow, T.G.B.; Welman, S.; Dimopoulos, G.E. and Moshal, M.G.: The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy. Anaesthesia and Intestive Care 6(1): 26–29 (1978).
Brogden, R.N.; Carmine, A.A.; Heel, R.C.; Speight T.M. and Avery, G.S.: Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24 (No. 5): 360–400 (1982).
Brouwers, J.R.B.J.; Assies, J.; Wiersinga, W.M.; Huizing, G. and Tytgat, G.N.: Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: A cross-over study in healthy volunteers. Clinical Endocrinology 12: 435–440 (1980).
Brown, R.D.; Kao, P. and Jiang, N.-S.: Metoclopramide acts directly on the adrenal cortex to stimulate the secretion of aldosterone. Clinical Research 27: 248A (1979).
Brown, R.D.; Wisgerhof, M.; Jiang, N.-S.; Kao, P. and Hegstad, R.: Effect of metoclopramide on the secretion and metabolism of aldosterone in man. Journal of Clinical Endocrinology and Metabolism 52(5): 1014–1018 (1981).
Bui, N.B.; Marit, G. and Hoerni, B.: High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting. Cancer Treatment Reports 66: 2107–2108 (1982).
Campbell, I.W.; Heading, R.C.; Tothill, R.; Buist, A.S.; Ewing, D.J. and Clarke, B.F.: Gastric emptying in diabetic autonomic neuropathy Gut 18(6): 462–467 (1977).
Campbell, B.C.; Elliott, H.L.; Hughes, M.A.; McLean, K.; Meredith, P.A. and Reid, J.L.: Effect of food on the pharmacokinetics of tolmesoxide in hypertensive patients. Proceedings of the B.P.S., p431, 16th–18th December (1980).
Cannon, J.G.: Chemistry of dopaminergic agonists. Advances in Neurology 9: 177 (1975).
Caralps, A.: Metoclopramide and renal failure. Lancet 1: 554 (1979).
Carey, R.M.; Thorner, M.O. and Ortt, E.M.: Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone. Journal of Clinical Investigation 63: 727–735 (1979).
Carey, R.M.; Thorner, M.O. and Ortt, E.M.: Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. Journal of Clinical Investigation 66(1): 10–18 (1980).
Charles, B.G.; Renshaw, P.J.; Kay, J.J. and Ravenscroft, P.J.: Effect of metoclopramide on the bioavailability of long-acting propranolol. British Journal of Clinical Pharmacology 11(5): 517–518 (1981).
Christie, D.L. and Ament, M.E.: A double-blind crossover study of metoclopramide versus placebo for facilitating passage of multipurpose biopsy tube. Gastroenterology 71(5): 726–728 (1976).
Cohen, S.: Reglan (metoclopramide) in gastroesophageal reflux disease. (Study 0801).
[Unpublished data, A.H. Robins. Cohen, S. and DiMarino, A.J.: Mechanism of action of metoclopramide on opossum lower esophageal and sphincter muscle. Gastroenterology 71 (6): 996–998 (1976).
Cohen, S.; Morris, D.W.; Schoen, H.J. and DiMarino, A.J.: The effect of oral and intravenous metoclopramide on human lower esophageal sphincter pressure Gastroenterology 70: 484–487 (1976).
Cohen, H.N.; Hay, I.D.; Thomson, J.A.; Logue, F.; Ratcliffe, W.A. and Beastall, G.H.: Metoclopramide stimulation: A test of growth hormone reserve in adolescent males. Clinical Endocrinology 11: 89–93 (1979).
Cohen, S.E.; Woods, W.A. and Wyner, J.: Antiemetic effect of metoclopramide and droperidol. Anesthesiology 55 (3a): 303 (1981).
Colls, B.M.; Ferry, D.G.; Gray, A.J.; Harvey, V.J. and McQueen, E.G.: The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. New Zealand Medical Journal 91(662): 449–451 (1980).
Cooke, R.D.; Comyn, DJ. and Ball, R.W.: Prevention of postoperative nausea and vomiting by domperidone. A double-blind randomized study using domperidone, metoclopramide and a placebo. South African Medical Journal 56(21): 827–829 (1979).
Corsini, G.U.; Del Zompo, M.; Cianchetti, C; Mangoni, A. and Gessa, G.L.: Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism. Psychopharmacology 47: 169–173 (1976).
Costall, B. and Naylor, R.J.: Neuroleptic and non-neuroleptic catalepsy. Arzneimíttel-Forschung 23: 674 (1973).
Costall, B. and Naylor, R.J.: The nucleus amygdaloideus centralis and neuroleptic activity in the rat. European Journal of Pharmacology 25: 138 (1974).
Costall, B. and Naylor, R.J.: A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. European Journal of Pharmacology 40: 9–19 (1976).
Crome, P.; Kimber, G.R.; Wainscott, G. and Widdop, B.: The effect of the simultaneous administration of oral metoclopramide on the absorption of paracetamol in healthy volunteers. Proceedings of the BPS, London 16–18 December 1980. Brit-ish Journal of Clinical Pharmacology 11: 430P (1981).
Dammacco, F.; Rigillo, N.; Chetri, G.; Torelli, C; Frezza, E.; Mastrangelo, C. and Zuccaro, A.: Prolactin secretion by metoclopramide in children. Acta Endocrinologica 85 (Suppl. 212): 51 (1977).
Davidson, E.D.; Hersh, T.; Ilaun, C. and Brooks, W.S.: Use of metoclopramide in patients with delayed gastric emptying following gastric surgery. American Surgeon 41(1): 40–44 (1977).
Davidson, E.D.; Hersh, T.; Brinner, R.A.; Barnett, S.M. and Boyle, L.P.: The effects of metoclopramide on postoperative ileus. A randomized double-blind study. Annals of Surgery 190(1): 27–30 (1979).
de Almeida, D.J.W.; Cameron, W.R. and Condie, R.: Treatment of dyspepsia in general practice. A multicentre trial. Practitioner 224: 105 (1980).
De Carle, D.J. and Christensen, J.: A dopamine receptor in esophageal smooth muscle of the opossum. Gastroenterology 70(2): 216–219 (1976).
Delitala, G.; Masala, Alagna, S. and Devilla, L.: Metoclopramide and prolactin secretion in man: Effects of pretreatment with L-dopa and 2-bromo-α-ergocryptine (CB-154). IRCS Medical Science: Clinical Pharmacology and Therapeutics 3: 274 (1975).
Denisoff, O. and Molle, L.: Binding study of benzamides to serum albumin by fluorescence probe technique. Arzneimittel-Forschung 28(11): 2156–2157 (1978).
Diamond, M.J.: Serum concentrations of lorazepam. British Journal of Anaesthesia 50(7): 730 (1978).
Diamond, M.J. and Keeri-Szanto: Reduction of postoperative vomiting by preoperative administration of oral metoclopramide. Canadian Anaesthetists’ Society Journal 27(1): 36–39 (1980).
Dolphin, A.; Jenner, P.; Marsden, CD.; Pycock, C. and Tarsy, D.: Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia 41: 133–138 (1975).
Donaldson, I.M.; Jenner, P.; Marsden, C.D.; Miller, R. and Peringer, E.: Is metoclopramide a directly acting dopamine receptor antagonist? British Journal of Pharmacology 56 (3) 373P (1976).
Doss, M.; Becker, U.; Peter, H.-J. and Kaffarnik, H.: Drug safety in porphyria: risks of valproate and metoclopramide. Lancet 2: 91 (1981).
Edwards, C.R.W.; Al-Dujaili, E.A.S.; Boscaro, M.; Quyyumi, S.; Miall, P.A. and Rees, L.H.: In vivo and in vitro studies on the effect of metoclopramide on aldosterone secretion. Clinical Endocrinology 13(1): 45–50 (1980).
Eisner, M.: Gastro-intestinal effects of metoclopramide in man. In vitro experiments with human smooth muscle preparations. British Medical Journal 4: 679 (1968).
Eisner, M.: Effect of metoclopramide on gastro-intestinal motility in man. Digestive Diseases 16: 409 (1971).
Engstrom, J.F. and Rhodes, J.B.: The effect of intravenous metoclopramide on esophageal dysfunction in scleroderma. Gastroenterology 72: 1158 (1977).
Fang, V.S.; Zimo, D.A. and Byyny, R.: Pituitary response to metoclopramide in the rat. Journal of Endocrinology 74(1): 155–156 (1977).
Fox, S. and Behar, J.: Pathogenesis of diabetic gastroparesis: A pharmacologic study. Gastroenterology 78(4): 757–763 (1980).
Frytak, S. and Moertel, CG.: Management of Nausea and Vomiting in the Cancer Patient. Journal of the American Medical Association 245(4): 393–396 (1981).
Frytak, S.; Moertel, C.G.; Eagan, R.T. and O’Fallon, J.R.: A double-blind comparison of metoclopramide (MCP) and prochlor-perazine (PCP) as antiemetics for platinum (CDDP) therapy. Proceedings of the American Society of Oncology 22: 421 (1981).
Fumiani, G.; Cego, S.P. and Guerra, A.: Metoclopramide intoxications. Minerva Pediatrica 27: 2246 (1975).
Gamble, J.A.S.; Gaston, J.H.; Nair, S.G. and Dundee, J.W.: Some pharmacological factors influencing the absorption of diazepam following oral administration British Journal of Anaesthesia 48: 1181–1185 (1976).
González, C.G.; Palomero, J.M.S. and Finamore, P.H.: Estudio clinico de la asociación dimenhidrinato-metoclopramida-piridoxina en el campo otorrinolaringológico. Annals of Otology, Rhinology and Laryngology, Ibero-American 4 (1-2): 135–140 (1977).
Gopichandran, T.D.; Ring, N.J. and Beckly, D.E.: Metoclopramide in double contrast barium meals. Clinical Radiology 31(4): 485–488 (1980).
Goslin, R.H. and Garnick, M.B.: Metoclopramide as an antiemetic in patients receiving cisplatin; in poster et al. (Eds) Treatment of Cancer Chemotherapy Induced Nausea and Vomiting, pp 159–165 (Masson Press, New York 1981).
Graf, K.-J.; Schmidt-Gollwitzer, M.; Horowski, R. and Dorow, R.: Effect of metoclopramide and lisuride on hypophyseal and gonadal function in men. Clinical Endocrinology 17: 243–251 (1982).
Graffner, C; Lagerström, P.-O.; Lundborg, P. and Rönn, O.: Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. British Journal of Clinical Pharmacology 8(5): 469–474 (1979).
Gralla, R.J.; Itri, L.M.; Pisko, S.E.; Squillante, A.E.; Kelsen, D.P.; Braun, D.W.Jr; Bordin, L.A.; Braun, T.J. and Young, C.W.: Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine 305: 905–909 and 948–949 (1981).
Gralla, R.J.; Tyson, L.B.; Clark, R.A.; Bordin, L.A.; Kelsen, D.P. and Kaiman, L.B.: Antiemetic trials with high dose metoclopramide: Superiority over THC, and preservation of efficacy in subsequent chemotherapy courses. Proceedings of American Society of Clinical Oncology 23: 58 (1982).
Grimes, J.D.: Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy. New England Journal of Medicine 305: 1417 (1981).
Grimes, J.D.; Hassan, M.N. and Preston, D.N.: Adverse neurologic effects of metoclopramide. Canadian Medical Association Journal 126: 23–25 (1982a).
Grimes, J.D.; Hassan, M.N. and Krelina, M.: Long term follow up of tardive dyskinesia due to metoclopramide. Lancet 2: 563 (1982b).
Guelrub, M.: Effect of intravenous metoclopramide on the incompetent lower oesophageal sphincter. American Journal of Gastroenterology 61: 119 (1974).
Gugler, R.; Brand, M. and Somogyi, A.: Impaired cimetidine absorption due to antacids and metoclopramide. European Journal of Clinical Pharmacology 20: 225–228 (1981).
Guzmán, V.; Toscano, G.; Canales, E.S. and Zárate, A.: Improvement of defective lactation by using oral metoclopramide: Acta Obstetricia et Gynaecologica Scandinavica 58(1): 53–55 (1979).
Häggström, J.E.: Metoclopramide-induced tardive dyskinesia. Läkartidningen 78(5): 361–363 (1981).
Hartong, W.A.; Moore, J. and Booth, J.P.: Metoclopramide in diabetic gastroparesis. Annals of Internal Medicine 86(6): 826 (1977).
Hay, A.M. and Man, W.K.: Effect of metoclopramide on guinea pig stomach. Critical dependence on intrinsic stores of acetylcholine. Gastroenterology 76: 492 (1979).
Hay, A.M.; Man, W.K. and McCloy, R.F.: Mechanism of action of metoclopramide: importance of intrinsic sources of acetylcholine. Gut 18: A950 (1977).
Healy, D.L. and Burger, H.G.: Sustained elevation of serum prolactin by metoclopramide: A clinical model of idopathic hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 46(5): 709–714 (1978).
Heitmann, P. and Möller, N.: The effect of metoclopramide on the gastro-oesophageal junctional zone and the distal oesophagus in man. Scandinavian Journal of Gastroenterology 5: 621 (1970).
Hey, V.M.F. and Ostick, D.G.: Metoclopramide and the gastrooesophageal sphincter. A study in pregnant women with heartburn. Anaesthesia 33: 462–465 (1978).
Hey, V.M.F.; Ostick, D.G.; Mazumder, J.K. and Lord, W.D.: Pethidine, metoclopramide and the gastro-oesophageal sphincter. A study in healthy volunteers. Anaesthesia 36(2): 173–176 (1981).
Ho, C.S.; Rubin, E. and Renouf, J.H.P.: Metoclopramide in gastrointestinal radiology. Journal of the Canadian Association of Radiologists 29: 51–55 (1978).
Homesley, H.D.; Gainey, J.M.; Jobson, V.W.; Welander, C.E.; Muss, H.B. and Wells, H.B.: Metoclopramide as an antiemetic in chemotherapy. New England Journal of Medicine 307: 250 (1982).
Hradsky, M. and Furugard, K.: The effect of metoclopramide (Primperan®) on the pyloric sphincter during gastroscopic examination. A double-blind investigation versus placebo. Up-sala Journal of Medical Science 83: 103–104 (1978).
Hughes, J.B.: Metoclopramide in migraine treatment. Medical Journal of Australia 2(17): 580 (1977).
Ijaiya, K.: Prolactin response to exercise, metoclopramide and other provocative agents in children. European Journal of Paediatrics 134(3): 231–237 (1980a).
Ijaiya, K.; Roth, B. and Schwenk, A.: The effects of arginine, insulin and metoclopramide on growth hormone, prolactin and cortisol release in children. Clinical Endocrinology 12: 589–594 (1980b).
Jackson, E.R. and Cardoni, A.A.: Metoclopramide (Regland®, A.H. Robins). Drug Intelligence and Clinical Pharmacy 14: 169–176 (1980).
Jacoby, H.I. and Brodie, D.A.: Gastro-intestinal actions of metoclopramide. An experimental study. Gastroenterology 52: 676 (1967).
Jenner, P. and Marsden, CD.: Tardive dyskinesias. Lancet 2: 900 (1979).
Jenner, P.; Clow, A.; Reavill, C; Theodorou, A. and Marsden, CD.: A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. Life Sciences 23(6): 545–549 (1978).
Johnson, A.G.: Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. British Medical Journal 2: 25–26 (1971).
Johnson, A.G.: Gastroduodenal motility and synchronisation. Postgraduate Medical Journal 49 (Suppl. 4): 29 (1973).
Johnson, A.G.; Mitchell, A.B.S.; Barnardo, D.E. and Kennedy, T.L.: Treatment of gastric ulcération. A controlled trial of metoclopramide (Maxolon). Clinical Trials Journal 14(1): 3–6 (1977).
Johnson, V.F.; O’Grady, J. and Bye, C: The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. British Journal of Clinical Pharmacology 5: 465–467 (1978).
Jones, A. and Harrop, C: Study of migraine and the treatment of acute attacks in industry. Journal of International Medical Research 8: 321 (1980).
Jones, CT.: Metoclopramide in the treatment of nausea. A double-blind trial. New Zealand Medical Journal 68: 388 (1968).
Judd, S.J.; Lazarus, L. and Smythe, G.: Prolactin secretion by metoclopramide in man. Journal of Clinical Endocrinology and Metabolism 43: 313–317 (1976).
Kahn, T.; Elias, E.G. and Mason, G.R.: A single dose of metoclopramide in the control of vomiting from cis-oichlorodiam-mineplatinum (II) in man. Cancer Treatment Reports 62(7): 1106–1107 (1978).
Kanto, J. and Katevuo, K.: The effect of drugs with different mechanisms of action on the contraction of the human gallbladder. International Journal of Clinical Pharmacology, Therapy and Toxicology 19(7): 303–309 (1981).
Kanto, J.; Allonen, H.; Jalonen, H. and Mäntyl, R. The effect of metoclopramide and propantheline on the gastrointestinal absorption of cimetidine. British Journal of Clinical Pharmacology 11(6): 629–631 (1981).
Karp, J.M.; Perkel, M.S.; Harsh, T. and McKinney, A.S.: Metoclopramide treatment of tardive dyskinesia. Journal of the American Medical Association 246(17): 1934–1935 (1981).
Katevuo, K.; Kanto, J. and Pihlajamaki, K.: The effect of metoclopramide on the contraction of the human gallbladder. Investigative Radiology 10: 197 (1975).
Kauppila, A. and Ylikorkala, O.: Effects of oral and intravenous TRH and metoclopramide on PRL and TSA secretion in women. Clinical Endocrinology 17: 617–623 (1982).
Kauppila, A.; Kivinen, S. and Ylikorkala, O.: A dose response relation between improved lactation and metoclopramide. Lancet 1: 1175–1177 (1981).
Kebabian, J.W. and Calne, D.B.: Multiple receptors for dopamine. Nature 277: 93–96 (1979).
Kebabian, J.W.; Tsuruta, K.; Cote, T.E. and Crewe, C.W.: The activity of substituted benzamides in biochemical models of dopamine receptors; in Rotrosen and Stanley (Eds) The Benzamides: Pharmacology, Neurobiology and Clinical Aspects, pp. 17–49 (Raven Press, New York 1982).
Kjaerulff, E. and Tøjner, H.: Therapy of the irritable colon in the office of the G.P. Controlled study of metoclopramide (Primperan). Ugeskrift for Laeger 139(39): 2322–2325 (1977).
Klein, R.L.; Militello, T.E. and Ballinger, C.M.: Antiemetic effect of metoclopramide … Evaluation in humans. Anaesthesia and Analgesia 47: 259 (1968).
Kuchel, O.; Buu, N.T.; Gutkowska, J. and Genest, J.: Treatment of severe orthostatic hypotension by metoclopramide. Annals of Internal Medicine 93(6): 841–843 (1980).
Lavy, S.; Melamed, E. and Penchas, S.: Tardive dyskinesia association with metoclopramide. British Medical Journal 1: 77–78 (1978).
Lewis, P.J.; Devenish, C and Kahn, C: Controlled trial of metoclopramide in the initiation of breast feeding. British Journal of Clinical Pharmacology 9(2): 217–219 (1980).
Longstreth, G.F.; Malagelada, J.-R. and Kelly, K.A.: Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Annals Intern. Med. 86(2): 195–196 (1977).
Longstreth, G.F.; Fox, D.D.; Youkeles, L.; Forsythe, A.B. and Wolochow, D.A.: Psyllium therapy in the irritable bowel syndrome. Annals of Internal Medicine 95: 53–56 (1981).
Malagelada, J.-R.: Physiologic basis and clinical significance of gastric emptying disorders. Digestive Diseases and Sciences 24: 657 (1979).
Malagelada, J.-R.; Rees, W.D.W.; Mazzotta, L.J. and Go, V.L.W.: Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: Effect of metoclopramide and bethanechol. Gastroenterology 78: 286–293 (1980).
Malagelada, J.-R.: Gastric emptying disorders. Clinical significance and treatment. Drugs 24: 353–359 (1982).
Mantero, F.; Opocher, G.; Boscaro, M.; Valpione, E.; Armanini, D. and Fallo, F.: Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism. Hormone and Metabolic Research 13: 464–467 (1981).
Masala, A.; Delitala, G.; Alagna, S.; Devilla, L.; Rovasio, P.P. and Lotti, G.: Effect of dopaminergic blockade on the secretion of growth hormone and prolactin in man. Metabolism 27(8): 921–926 (1978).
Matsumura, S.; Onishi, T.; Miyai, K.; Mor, S.; Uozumi, T. and Kumahara, Y.: Effect of metoclopramide on prolactin secretion in normal subjects. Hiroshima Journal of Medical Sciences 26(1): 35–38 (1977).
McCallum, R.W.; Sowers, J.R.; Hershman, J.M. and Sturdevant, R.A.L.: Metoclopramide stimulates prolactin secretion in man. Clinical Research 23(4): 479A (1975a).
McCallum, R.W.; Kline, M.M.; Curry, N. and Sturdevant, R.A.L.: Comparative effects of metoclopramide and bethanechol on lower oesophageal sphincter pressure in reflux patients. Gastroenterology 68: 1114–1118 (1975b).
McCallum, R.W.; Ippoliti, A.F.; Cooner, C and Sturdevant, R.A.L.: A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. New England Journal of Medicine 296(7): 354–357 (1977).
Meltzer, H.Y.; So, R.; Miller, R.J. and Fang, V.S.: Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of H-3-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion. Life Sciences 25: 573–584 (1979).
Meltzger, W.H.; Cano, R. and Sturdevant, R.A.L.: Effect of metoclopramide in chronic gastric retention after gastric surgery. Gastroenterology 71(1): 30–32 (1976).
Millar, J.W.; Heading, R.C; Campbell, I.W.; Ewing, DJ.; McLoughlin, G.P. and Clarke, B.F.: Metoclopramide in diabetic gastric atony. Scottish Medical Journal 25: 176 (1980).
Moldofsky, H.; Jeuniewic, N. and Garfinkel, P.E.: Preliminary report on metoclopramide in anorexia nervosa; in Vigersky (Eds) Anorexia Nervosa, pp. 373–375 (Raven Press, New York, 1977).
Morrow, G.R.; Arseneau, J.C.; Asbury, R.F.; Bennett, J.M. and Boros, L.: Anticipatory nausea and vomiting with chemotherapy. New England Journal of Medicine 306(7): 431–432 (1982).
Nakra, B.R.S.; Bond, A.J. and Lader, M.H.: Comparative psychotropic effects of metoclopramide and prochlorperazine in normal subjects. Journal of Clinical Pharmacology 15: 449 (1975).
Norbiato, G.; Bevilacqua, M.; Moroni, C; Raggi, U. and Micossi, P.: Effect of metoclopramide on aldosterone secretion in man. Acta Endocrinologica (Suppl.): 208–214 (1977).
Norbiato, G.; Bevilacqua, M; Raggi, U.; Micossi, P.; Nitti, F.; Lanfredini, M. and Barbieri, S.: Effect of metoclopramide, a dopaminergic inhibitor, on renin and aldosterone in idiopathic edema: possible therapeutic approach with levodopa and carbidopa. Journal of Clinical Endocrinology and Metabolism 48: 37 (1979).
Ogihara, T.; Matsumara, S.; Onishi, T.; Miyai, K.; Uozumi, T. and Kumahara, Y.: Effect of metoclopramide-induced prolactin on aldosterone secretion in normal subjects. Life Sciences 20: 523–526 (1977).
Oigaard, A. and Fleckenstein, P.: The effect of metoclopramide, pyridostigmine bromide and cholecystokinin on duodenal motility. Scandinavian Journal of Gastroenterology 10 (Suppl. 35): 30 (1975).
Okwuasaba, F.K. and Hamilton, J.T.: The effect of metoclopramide in intestinal muscle responses and the peristaltic reflex in vitro. Canadian Journal of Physiology and Pharmacology 54: 393–404 (1976).
Olesen, J.; Aebelholt, A. and Veilis, B.: The Copenhagen Acute Headache Clinic: Organisation, patient material and treatment results. Headache 19: 223–227 (1979).
Olsson, G.L. and Hallen, B.: Pharmacological evaluation of the stomach with metoclopramide. Acta Anaesthesiologica Scandinavica 26: 417–420 (1982).
Pajewski, M.; Eshchar, J. and Manor, A.: Visualisation of the small intestine by double contrast. Clinical Radiology 26: 491–493 (1975).
Park, G.R.: Hypotension following metoclopramide administration during hypotensive anaesthesia for intracranial aneurysm. British Journal of Anaesthesia 50(12): 1268–1269 (1978).
Pauli, A. and Grant, A.K.: A controlled trial of metoclopramide in reflux oesophagitis. Medical Journal of Australia 2: 627–629 (1974).
Pegg, M.S.: Hypotension following metoclopramide injection. Anaesthesia 35(6): 615 (1980).
Perkel, M.S.; Hersh, T.; Moore, C. and Davidson, E.O.: Metoclopramide therapy in fifty-five patients with delayed gastric emptying. American Journal of Gastroenterology 74: 231–236 (1980).
Perkel, M.S.; Fajman, W.A.; Hersh, T.; Moore, C; Davidson, E.D. and Haun, C: Comparison of the barium test meal and the gamma camera scanning technic in measuring gastric emptying. Southern Medical Journal 74(9): 1065–1068 (1981).
Pinder, R.M.; Brogden, R.N.; Sawyer, P.R.; Speight, T.M. and Avery, G.S.: Metoclopramide: A review of its pharmacological properties and clinical use. Drugs 12: 81–131 (1976).
Pinto, M.; Cavagnini, F.; Invitti, C.; Maraschini, C. and DiLandro, A.: Effect of metoclopramide on cortisol and growth hormone secretion in response to ACTH. Acta Endocrinologica 85 (Suppl. 212): 164 (1977).
Plouin, P.F.; Menard, J. and Corvol, P.: Hypertensive crisis in patient with phaeochromocytoma given metoclopramide. Lancet 2: 1357–1358 (1976).
Ramirez-Mata, M.; Ibanez, G. and Alarcon-Segovia, D.: Stimulatory effect of metoclopramide on the esophagus and lower esöphageal sphincter of patients with PSS. Arthritis and Rheumatism 20(1): 30–34 (1977).
Ramsbottom, N. and Hunt, J.N.: Studies of the effect of metoclopramide and-apomorphine on gastric emptying and secretion in man. Gut 11: 989 (1970).
Rampton, D.S.: Hypertensive crisis in a patient given Sinemet, metoclopramide, and amitriptyline. British Medical Journal 2: 607–608 (1977).
Regardh, C.G.; Lundborg, P. and Persson, B.A.: The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharmaceutics and Drug Disposition 2: 79–87 (1981).
Reynolds, G.J.: Metoclopramide in young children. British Medical Journal 2: 1713 (1978).
Rhodes, J.B.; Engstrom, J. and Stone, K.F.: Metoclopramide reduces te distress associated with colon cleansing by an oral electrolyte overload. Gastrointestinal Endoscopy 24(4): 162–163 (1978).
Rhodes, J.B.; Robinson, R.G. and McBride, N.: Sudden onset of slow gastric emptying of food. Gastroenterology 77: 569–571 (1979).
Riddall, D.R. and Leavens, W.J.: Affinities of drugs for the agonist and antagonist states of the dopamine receptor. European Journal of Pharmacology 51: 187–188 (1978).
Robins, A.H. Company: Investigational brochure AHR-3070C (1980).
Ross-Lee, L.M.; Eadie, M.J.; Bochner, F.; Hooper, W.D. and Tyrer, J.H.: Electron-capture. Gas Chromatographic assay for metoclopramide in plasma. Journal of Chromatography 183: 175–184 (1980).
Ross-Lee, L.M.; Eadie, M.J.; Hooper, W.D. and Bochner, F.: Single-dose pharmacokinetics of metoclopramide. European Journal of Clinical Pharmacology 20: 465–471 (1981).
Ross-Lee, L.; Heazlewood, V.; Tyrer, J.H. and Eadie, M.J.: Aspirin treatment of migraine attacks. Plasma drug level data. Cephalgia 2: 9 (1982).
Rotrosen, J.; Stanley, M.; Lautin, A.; Wazer, D. and Gershon, S.: Discrimination of functionally heterogeneous receptor sub-populations: Antipsychotic and antidopaminergic properties of metoclopramide. Psychopharmacology Bulletin 17(1): 110–113 (1981).
Saleh, J.W. and Lebwohl, P.: Metoclopramide-induced gastric emptying in patients with anorexia nervosa. American Journal of Gastroenterology 74(2): 127–132 (1980).
Schelin, S.: Observations on the effect of metoclopramide (Primperan®) on the human ureter. Scandinavian Journal of Urology and Nephrology 13: 79–82 (1979).
Schulze-Delrieu, K.: Drug therapy. Metoclopramide. New England Journal of Medicine 305: 28–33 (1981).
Schulze-Delrieu, K.: Metoclopramide. Gastroenterology 77: 768–779 (1979).
Schulze, H.-J. and Winkler, J.W.: A serious incidence after IV injection of Cerucal. Deutsche Gesundheitswesen 33(3): 131–134 (1978).
Schütz, E.: Fortschritte in der Therapie des Ulcus duodeni. Münchener Medizinische Wochenschrift 118(8): 231–234 (1976).
Seigel, L.J. and Longo, D.L.: The control of chemotherapy-induced emesis. Annals of Internal Medicine 95: 352–359 (1981).
Shader, R.I. and Greenblatt, D.J.: Differing interpretations of trazodone and metoclopramide studies and more bias on teaching. Journal of Clinical Psychopharmacology 2: 89–90 (1982).
Shaklai, M.; Pinkhas, J. and De Vries, A.: Metoclopramide and cardiac arrhythmia. British Medical Journal 2: 385 (1974).
Sheridan, C.; Pradeep, C; Jacinto, M. and Greenwald, E.S.: Transient hypertension after high doses of metoclopramide. New England Journal of Medicine 307: 1346 (1982).
Singh, M.S. and Lean, T.H.: The use of metoclopramide (Maxlon) in hyperemesis gravidarum. Proceedings of the Obstetrical and Gynaecological Society, Singapore 1: 43 (1970).
Skucas, J. and House, A.J.S.: Evaluation of metoclopramide as an aid in double-contrast upper gastro-intestinal examinations. Investigative Radiology 13(5): 420 (1978).
Slettnes, O. and Sjaastad, O.: Metoclopramide during attacks of migraine; in Headache: New Vistas, p. 201–204 (Biomedical Press, Florence, Italy 1977).
Snape, W.J.; Battle, W.M.; Schwartz, S.S.; Braunstein, S.N.; Goldstein, H.A. and Alavi, A.: Metoclopramide to treat gastroparesis due to diabetes mellitus. A double-blind, controlled trial. Annals of Internal Medicine 96: 444–446 (1982).
Sowers, J.R.; McCallum, R.W.; Hershman, J.M.; Carlson, H.E. and Sturdevant, R.A.L.: Effect of metoclopramide on pituitary hormone secretion in man. Clinical Research 24(3): 278A (1976).
Sowers, J.R.; Carlson, H.E.; Brautbar, N. and Hershman, J.M.: Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. Journal of Clinical Endocrinology and Metabolism 44(2): 237–241 (1977).
Sowers, J.R.; Sharp, B. and McCallum, R.W.: Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotrophin, prolactin, renin, aldosterone and 18-hydroxycorticosterone secretion in man. Journal of Clinical Endocrinology and Metabolism 54: 69–71 (1982).
Spitz, I.M.; Zylber, E.; Leroith, D.; Shapiro, M.; Luboshitsky, R.; Jersky, J. and Hoffman, J.: The human pancreatic polypeptide response to metoclopramide. Diabetes 27 (Suppl. 2): 506 (1978).
Stadaas, J.O. and Aune, S.: The effect of metoclopramide (Primperan) on gastric motility before and after vagotomy in man. Scandinavian Journal of Gastroenterology 6: 17 (1971).
Stanciu, C. and Bennett, J.R.: Metoclopramide in gastro-oesophageal reflux. Gut 14: 275 (1973).
Stanley, M. and Wuk, S.: Striatal DOPAC elevation predicts efficacy of metoclopramide. Life Sciences 24: 1907–1912 (1979).
Stanley, M.; Rotrosen, J.; Lautin, A.; Wazer, D. and Gershon, S.: Tardive dyskinesia and metoclopramide. Lancet 2: 1190 (1979).
Stanley, M.; Lautin, A.; Rotrosen, J.; Gershon, S. and Kleinberg, D.: Metoclopramide: Antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology 71: 219–225 (1980).
Steeves, R.A.; Robinson, D.; McKenzie, M.W. and Justus, P.G.: Effects of metoclopramide on the pharmacokinetics of a slow-release theophylline product. Clinical Pharmacy 1: 356 (1982).
Strum, S.B.; McDermed, J.E.; Opfell, R.W. and Riech, L.P.: Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. Journal of American Medical Association 247(19): 2683–2686 (1982).
Takaori, S.; Nakai, Y.; Matsuoka, I.; Sasa, M. and Shimamoto, K.: Pharmacological action of N-(Diethylaminoethyl)-2-methoxy-4-amino-5-cholorobenzamide dihydrochloride. Current Clinics 1: 158 (1967).
Takaori, S.; Nakai, Y.; Matsuoka, I.; Sasa, M.; Fukuda, N. and Shimamoto, K.: The mechanism of antagonism between apomorphine and metoclopramide on unit discharges from nuclear structures in the brainstem of the cat. International Journal of Neuropharmacology 7: 115 (1968).
Tarn, Y.K. and Axelson, J.E.: Sensitive electron-capture GLC determination of metoclopramide in biological fluids. Journal of Pharmaceutical Sciences 67(8): 1073–1077 (1978).
Tarn, Y.K.; Axelson, J.E.; McErlane, B.; Kapil, R.P.; Riggs, K.W.; Ongley, R. and Price, J.D.E.: The pharmacokinetics of meto clopramide in rats with experimental renal and hepatic dysfunction. Journal of Pharmacology and Experimental Therapeutics 219(1): 141–146 (1981).
Telander, R.L.; Morgan, K.G.; Kreulen, D.L.; Schmalz, P.F.; Kelly, K.A. and Szurszewski, J.H.: Human gastric atony with tachygastria and gastric retention. Gastroenterology 75(3): 497–501 (1978).
Teng, L.; Bruce, R.B. and Dunning, L.K.: Metoclopramide metabolism and determination by high-pressure liquid chromatography. Journal of Pharmaceutical Sciences 66(11): 1615–1618 (1977).
Thorburn, C.W. and Sowton, E.: The haemodynamic effects of metoclopramide. Postgraduate Medical Journal 49 (Suppl. 4): 22 (1973).
Tokola, R.A. and Neuvonen, P.J.: Effects of acute migraine and metoclopramide on absorption of tolfenamic acid. Acta Neurologica Scandinavica 65 (Suppl. 90): 79 (1982).
Trafford, J.A.P.; Fisher, A.M.H.; Marshall, S. and Douthwaite, A.H.: Metoclopramide (Maxolon) —A new anti-emetic. British Journal of Clinical Practice 21: 457 (1967).
Vaidyanathan, S.; Rao, M.S.; Bapna, B.C.; Chary, K.S.N. and Swamy, R.P.: Role of dopamine receptors in vesicourethral function. A urodynamic study with dopamine receptor antagonist metoclopramide. Annals of Clinical Research 12(1): 1–4 (1980a).
Vaidyanathan, S.; Rao, M.S.; Bapna, B.C.; Sharma, P.L.; Chary, K.S.N. and Swamy, R.P.: Further observations on vesicourethral dopamine receptors —a urodynamic study with haloperidol. Annals of Clinical Research 12: 49–51 (1980b).
Venables, C.W.; Bell, D. and Eccleston, D.: A double-blind study of metoclopramide in symptomatic peptic oesophagitis. Postgraduate Medical Journal (July Suppl.): 73–76 (1973).
Volans, G.N.: The effect of metoclopramide on the absorption of effervescent aspirin in migraine. British Journal of Clinical Pharmacology 2: 57–63 (1975).
Wainscott, G.; Kaspi, T. and Volans, G.N.: The influence of thiethylperazine on the absorption of effervescent aspirin in migraine. British Journal of Clinical Pharmacology 3: 1015–1021 (1976).
Wandless, I.; Evans, J.G. and Jackson, M: Fever associated with metoclopramide-induced dystonia. Lancet 1: 1255–1256 (1980).
Wazer, D.E.; Rotrosen, J. and Stanley, M: The benzamides: Evidence for action at dopamine receptors —shortcomings of current models; in Rotrosen and Stanley (Eds) The Benzamides: Pharmacology, Neurobiology and Clinical Aspects, pp. 83–95 (Raven Press, New York 1982).
Wilkinson, M.; Williams, K. and Leyton, M.: Observations on the treatment of an acute attack of migraine. Research and Clinical Study of Headache 6: 141–146 (1978).
Wing, L.M.H.; Meffin, P.J.; Grygiel, J.J.; Smith, K.J. and Birkett, D.J.: The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. British Journal of Clinical Pharmacology 9(5): 505–509 (1980).
Winnan, J.; Avella, J.; Callachan, C. and McCallum, R.W.: Double-blind trial of metoclopramide versus placebo-antacid in symptomatic gastroesophageal reflux. Gastroenterology 78(5): 1292 (1980).
Wright, R.A. and MacGregor, I.L.: Effect of metoclopramide on gastric stasis after reversed jejunal loop for postvagotomy diarrhoea. American Journal of Gastroenterology 72: 441–443 (1979).
Zanella, M.T. and Bravo, E.L.: In vitro and in vivo evidence for an indirect mechanism mediating enhanced aldosterone secretion by metoclopramide. Endocrinology 111: 1620–1625 (1982).
Zar, M.A.; Ebong, O.O. and Bateman, D.N.: Effect of metoclo-pramide in guinea-pig ileum longitudinal muscle: evidence against dopamine-mediation. Gut 23: 66–70 (1982).
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: O.E. Akwari, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA; D.N. Bateman, Department of Pharmacological Sciences, University of Newcastle upon Tyne, England; S. Cohen, Gastrointestinal Section of the Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA; R.D. Cooke, Department of Anaesthetics, University of Cape Town, Cape, South Africa; R.J. Gralla, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Developmental Chemotherapy and Solid Tumor Services, New York, USA; J.D. Grimes, Department of Medicine (Neurology), University of Ottawa, OntariO, Canada; A.G. Johnson, University Surgical Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, England; J.W. Kebabian, Biochemical Neuropharmacology Section, National Institutes of Health, Bethesda, Maryland, USA; R.W. McCallum, Gastroenterology Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.; J. R. Malagelada, Gastroenterology Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; L. Ross-Lee, Department of Medicine, University of Queensland, Brisbane, Australia; J. Rotrosen, Veterans Administration Medical Center, New York, USA; K. Schulze, Department of Internal Medicine, The University of Iowa, Iowa City, USA.
Rights and permissions
About this article
Cite this article
Harrington, R.A., Hamilton, C.W., Brogden, R.N. et al. Metoclopramide. Drugs 25, 451–494 (1983). https://doi.org/10.2165/00003495-198325050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198325050-00002
Keywords
- Migraine
- Gastric Emptying
- Metoclopramide
- Tardive Dyskinesia
- Gastroparesis